Company Shares of Organovo Holdings (NYSEMKT:ONVO) Rally 1.84%

Organovo Holdings (NYSEMKT:ONVO) : Traders are bullish on Organovo Holdings (NYSEMKT:ONVO) as it has outperformed the S&P 500 by a wide margin of 23.17% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.55%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.84% in the last 1 week, and is up 25.16% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have rallied 0.52% from its 1 Year high price. On Jul 6, 2016, the shares registered one year high at $4.35 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $3.18 and the 200 Day Moving Average price is recorded at $2.53.

The stock has recorded a 20-day Moving Average of 15.1% and the 50-Day Moving Average is 30.18%.


Organovo Holdings (NYSEMKT:ONVO): On Fridays trading session , Opening price of the stock was $3.96 with an intraday high of $4. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $3.75. However, the stock managed to close at $3.88, a loss of 1.52% for the day. On the previous day, the stock had closed at $3.94. The total traded volume of the day was 1,549,720 shares.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Organovo Holdings, Inc., Baltera Robert Jr. had sold 6,000 shares worth of $24,180 in a transaction dated September 21, 2015. In this transaction, 6,000 shares were sold at $4.03 per share.

Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.